Advertisement

Bio-Rad Laboratories, Inc. BIO

Set alert

Price alert · BIO

All alert types
366.16 USD -6.02 -1.62%

At close · Nov 2

366.16 0.00 0.00%

After hours · Nov 2, 4:24 PM ET

Bid
365.11 × 160
Ask
366.50 × 40
361.27 Day range 377.90
236.73 52-week range 396.23
YTD
+20.85%
1 year
+14.59%
Open
374.79
Prev close
372.18
Mkt cap
9.80B
Vol
211.83K
Avg vol
255.34K
EPS
7.89
P/E
46.41
Div yield
0.00%
More statistics
Low
361.27
High
377.90
Forward P/E
37.57
Beta
1.06
Short ratio
4.17
Inst. own
91.74%
Dividend
0.00
Ex-div date
Earnings
Nov 4, 2026
50-d avg
374.80
200-d avg
313.41
1y target
335.00

1Y chart

Chart tools
Interval

Events in this range
  • Feb 12, 2026Earnings: 2.51; estimate 2.57; surprise -2.33%
  • Apr 7, 2026Downgrade: Citigroup · Buy → Neutral
  • Apr 30, 2026Earnings: 1.89; estimate 1.97; surprise -4.06%
  • May 1, 2026Rating: Wells Fargo · Equal-Weight → Equal-Weight
  • Aug 4, 2026Earnings: 2.62; estimate 1.75; surprise 49.71%
  • Aug 5, 2026Rating: Wells Fargo · Equal-Weight → Equal-Weight
  • Aug 5, 2026Rating: RBC Capital · Outperform → Outperform
  • Aug 5, 2026Rating: Citigroup · Neutral → Neutral
  • Aug 7, 2026Rating: RBC Capital · Outperform → Outperform
Signals (61)
NameDateAgo
SMA: BearishOct 30, 20263 days ago
SMA: BullishOct 27, 20266 days ago
MACD: Buy SignalOct 23, 20261 week ago
SMA: BearishOct 7, 20263 weeks ago
SMA: BullishOct 2, 20261 month ago
SMA: BearishOct 1, 20261 month ago
RSI: OverboughtSep 2, 20262 months ago
MACD: Sell SignalSep 1, 20262 months ago
RSI: OverboughtAug 19, 20262 months ago
RSI: OverboughtAug 5, 20262 months ago
RSI: OverboughtAug 3, 20263 months ago
RSI: OverboughtJul 28, 20263 months ago
MACD: Buy SignalJul 10, 20263 months ago
SMA: BullishJul 9, 20263 months ago
MACD: Sell SignalJul 8, 20263 months ago
SMA: BearishJul 7, 20263 months ago
SMA: BullishJul 1, 20264 months ago
SMA: BearishJun 30, 20264 months ago
MACD: Buy SignalJun 29, 20264 months ago
SMA: BullishJun 25, 20264 months ago
SMA: BullishJun 25, 20264 months ago
SMA: BearishJun 18, 20264 months ago
SMA: BearishJun 10, 20264 months ago
SMA: BullishJun 9, 20264 months ago
MACD: Sell SignalJun 9, 20264 months ago
SMA: BearishJun 8, 20264 months ago
RSI: OverboughtMay 28, 20265 months ago
SMA: BullishMay 26, 20265 months ago
SMA: BullishMay 18, 20265 months ago
MACD: Buy SignalMay 18, 20265 months ago
RSI: OversoldMay 11, 20265 months ago
SMA: BearishMay 1, 20266 months ago
SMA: BullishApr 30, 20266 months ago
SMA: BearishApr 29, 20266 months ago
MACD: Sell SignalApr 27, 20266 months ago
SMA: BearishApr 23, 20266 months ago
RSI: OverboughtApr 21, 20266 months ago
SMA: BullishApr 14, 20266 months ago
SMA: BullishApr 10, 20266 months ago
SMA: BearishApr 9, 20266 months ago
SMA: BullishApr 8, 20266 months ago
SMA: BearishApr 6, 20267 months ago
SMA: BullishApr 2, 20267 months ago
MACD: Buy SignalMar 17, 20267 months ago
MACD: Sell SignalMar 12, 20267 months ago
SMA: BearishMar 5, 20268 months ago
SMA: BullishMar 4, 20268 months ago
MACD: Buy SignalFeb 27, 20268 months ago
SMA: BearishFeb 13, 20268 months ago
RSI: OversoldFeb 13, 20268 months ago
MACD: Sell SignalJan 21, 20269 months ago
SMA: BearishJan 20, 20269 months ago
SMA: BullishJan 5, 202610 months ago
MACD: Buy SignalJan 2, 202610 months ago
SMA: BearishDec 11, 202510 months ago
SMA: BullishDec 10, 202510 months ago
SMA: BearishDec 8, 202510 months ago
MACD: Sell SignalDec 5, 202511 months ago
MACD: Buy SignalNov 25, 202511 months ago
SMA: BullishNov 21, 202511 months ago
SMA: BearishNov 20, 202511 months ago

Key statistics

Market cap
9.80B
Enterprise value
9.70B
Trailing P/E
46.42
Forward P/E
37.57
PEG ratio
4.01
Price / sales
3.79
Price / book
1.36
EPS (TTM)
7.89
Beta
1.06
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
8.59%
Revenue (TTM)
2.59B
Revenue growth
-0.10%
Free cash flow
283.19M
Total cash
1.62B
Total debt
1.37B
Return on equity
3.11%
Shares outstanding
21.70M
Short % of float
6.91%
50-day average
374.80
200-day average
313.41

Analyst view

Consensus: hold

Hold
Price target (mean) 335.00 -8.5% downside
Target (low)
280.00
Target (mean)
335.00
Target (high)
390.00
Ratings (0m) 3 1 buy · 1 hold · 1 sell
  • Strong buy1
  • Buy0
  • Hold1
  • Sell0
  • Strong sell1

Next earnings

Nov 4, 2026

Expected Nov 4, 2026. Consensus EPS estimate 2.23.

Earnings history

Financials — quick view

All financials
BIO Revenue — quarterly 651.00M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
BIO Net income — quarterly 371.40M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
BIO EPS — quarterly 13.89
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

BIO recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 4, 2026Sep 30, 20262.23———
Aug 4, 2026Jun 30, 20261.752.62+0.87+49.71%
Apr 30, 2026Mar 31, 20261.971.89-0.08-4.06%
Feb 12, 2026Dec 31, 20252.572.51-0.06-2.33%
Oct 29, 2025Sep 30, 20252.302.26-0.04-1.74%
Jul 31, 2025Jun 30, 20251.932.61+0.68+35.23%

Upgrades / downgrades

BIO analyst upgrades and downgrades
DateFirmActionFromTo
Aug 7, 2026RBC CapitalmainOutperformOutperform
Aug 5, 2026CitigroupmainNeutralNeutral
Aug 5, 2026RBC CapitalmainOutperformOutperform
Aug 5, 2026Wells FargomainEqual-WeightEqual-Weight
May 1, 2026Wells FargomainEqual-WeightEqual-Weight
Apr 7, 2026CitigroupdownBuyNeutral

About Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Sector
Healthcare
Industry
Medical Devices
Country
United States
Website
bio-rad.com

News

Your note

Sign in to keep a note on BIO — it syncs with the Stock Master app.

Insider holders

BIO insider holders
InsiderRelationLatest transactionDateShares held
ALLISON SCHWARTZDirectorConversion of Exercise of derivative securitySep 3, 20261,734
BARRY JAMESOfficerConversion of Exercise of derivative securitySep 3, 20262,024
COREY COLLEENOfficerConversion of Exercise of derivative securitySep 4, 202519,550
CROWLEY MICHAEL WOfficerConversion of Exercise of derivative securityMar 13, 20258,171
DIVINCENZO JONATHAN PPresidentConversion of Exercise of derivative securityOct 22, 20262,881
ENGELHARDT EVA ANETTEOfficerConversion of Exercise of derivative securitySep 3, 20261,828

Institution ownership

BIO institution ownership
Holder% heldSharesValueReported
First Eagle Investment Management, LLC12.02%2,606,219954.48MJun 29, 2026
Blackrock Inc.7.84%1,698,929622.20MJun 29, 2026
Dimensional Fund Advisors LP4.36%944,548345.92MJun 29, 2026
Vanguard Capital Management LLC3.81%826,972302.86MJun 29, 2026
Vanguard Portfolio Management LLC3.77%816,198298.92MJun 29, 2026
Ariel Investments, LLC3.77%816,751299.12MJun 29, 2026

Fund ownership

BIO fund ownership
Holder% heldSharesValueReported
First Eagle Funds-First Eagle Global Fund8.67%1,878,739688.05MJul 30, 2026
SmallCap World Fund Inc4.29%930,906340.93MSep 29, 2026
iShares Trust-iShares Core S&P Mid-Cap ETF2.99%648,604237.54MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.70%584,782214.16MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund1.95%423,193154.99MJun 29, 2026
Ariel Investment Trust-Ariel Fund1.61%349,270127.91MJun 29, 2026
Advertisement